Loading…
SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.
Also known as: BRIDGEBIO PHARMA, INC., BridgeBio Pharma, Inc., BRIDGEBIO PHARMA, INC.
Client-Reported Lobbying Expenses
$3.8M
20 filings
Firm Income Reported for This Client
$230K
Not substituted for client expenses
SEC Insider
$1.69B
1,169 transactions
Summary
BRIDGEBIO PHARMA, INC. (BBIO) is an organization. Its political footprint includes $3.8 million in client-reported lobbying expenses, $230K in lobbying-firm income reported for this client. Lobbying activity focuses on Pharmacy, Health Issues, Medicare/Medicaid. Their largest government contract source is Department of Veterans Affairs at $0. Political activity spans from 2023 to 2026.
These are different money flows and are not added together: contributions and lobbying expenses flow out, while contract awards flow to the organization.
Lobbying Spend Trend
↑ 80% YoY
2025: $1.5M (complete years)
Insider Trading
47 insiders